The CD4 molecule is a high affinity receptor for the human immunodeficiency virus (HIV) envelope glycoprotein (gpl60 or gpl20). This glycoprotein is expressed on the surface membrane of cells infected with HIV. It has, therefore, been suggested that a soluble form of CD4 might be used as a targeting agent to deliver toxins selectively to cells infected with HIV.
Introduction
The CD4 molecule is a high affinity receptor for the human immunodeficiency virus (HIV) envelope glycoprotein (1) . Anti-CD4 monoclonal antibodies block HIV infection of target cells in vitro (2, 3) . Cells not expressing the CD4 molecule may become susceptible to HIV infection following transfection with the CD4 gene (4) . Moreover, it has recently been shown that a soluble form of the extracellular portion of the CD4 molecule created through recombinant DNA technology can block HIV infection of cells in vitro (5) (6) (7) (8) (9) .
It has been suggested that a soluble form ofCD4 may prove valuable in the therapy of HIV-infected individuals by directly competing with cell surface expressed CD4 molecules for the binding of virus. In fact, recent studies in simian immunodeficiency virus-infected rhesus monkeys and HIV-infected humans suggest that this approach may be oftherapeutic value (10) (11) (12) . It has also been proposed that soluble CD4 might be employed for the targeting oftoxins to cells infected with HIV. Thus, cells infected with HIV and expressing virus envelope glycoprotein on their surface might specifically bind a CD4-toxin conjugate and be killed as a result of that interaction. In vitro experiments have indicated that this approach may be feasible (13) (14) (15) (16) .
We have recently initiated studies to explore the possible use of CD4-toxin conjugates in the treatment of AIDS. In these experiments, we demonstrate that CD4-Pseudomonas exotoxin (PE)' conjugates can inhibit HIV replication in cell populations in vitro. However, this inhibition of virus replication appears to be incomplete. CD4-toxin proteins. The CD4-PE constructs used in these studies were expressed by Escherichia coli renatured and purified by immune-affinity chromatography using an anti-CD4 monoclonal antibody bound to BrCN-activated Sepharose as described by Winkler et al. (manuscript in preparation) (Fig. 1) . Both contained amino acids 1-181 of the human CD4 molecule, its two amino-terminal Ig-like domains (16a, 16b). The shorter construct, CD4-PE(364), contained amino acids 250-613 of PE, its 364 carboxy-terminal amino acids (16c). This consists of domains II (the portion required for translocation of the toxin into the cytoplasm of a target cell), Ib, and III (the portion responsible for ADP-ribosylation ofelongation factor 2) (16d). The longer construct, CD4-PE(392), contained, in addition, the carboxy-terminal 28 amino acids of domain I which are involved in cell recognition (16d (17, 18) . PBLs were incubated at a concentration of 1.5 X 107/ml for 40 min at 4VC with anti-CD8 MAb (7PT3F9) in ascites form at a dilution of 1:125. The cells were then washed twice with PBS and resuspended in PBS at a concentration of4 X 106 cells/ml. 3 ml of this cell suspension was plated on a 10-cm plastic petri dish coated with 10 Ag rabbit anti-mouse Ig (Dako Corp., Santa Barbara, CA) and preincubated with 10 ml ofPBS supplemented with 2% FCS. Cells were incubated on these dishes for 70 min at 4VC.
The dishes were then swirled and cells in the supernatant were harvested. These cells were used as a CD8+ cell-depleted population. CD8+ cell-depleted PBLs were maintained in RPMI 1640 medium supplemented with 10% FCS and 20 U/ml IL-2 at a concentration of 1 X 106 cells/ml.
Reverse transcriptase (RT) assay. RT activities of culture supernatants were measured as described (19) . Briefly, 1.4 ml of each supernatant was centrifuged in a 1.5-ml Eppendorftube at 12,000gfor 90 min. The cells and HIV-infected H9 cells were cocultivated in the presence of 12.0-nM CD4-PE(392). CD4-PE was, however, removed from the cultures on day 3, day 7, or day 10. In each of these instances, HIV replication was detected immediately after CD4-PE was removed from the cultures (Fig. 4) . Therefore, a 12.0-nM concentration of CD4-PE inhibited HIV replication only as long as it was present in culture. Moreover, when CD4-PE was maintained in a similar culture system for 10 d at a 6.0-nM rather than 12.0-nM concentration, a concentration that fully abrogated HIV replication for a 7-d culture period, virus replication was readily demonstrable by day 10 (Fig. 5 ). CD4-PE does not block transmission ofHIVfrom infected to uninfected H9 cells. Thus, CD4-PE exposure appeared to delay but did not abort the generation of RT activity in these cultures. This HIV replication could reflect the transmission in culture of HIV from virus-infected to virus-free H9 cells. It could, however, also simply represent the gradual expansion of the HIV-infected H9 cells originally introduced in vitro as a source of virus. To differentiate between these two possibilities, cell-associated HIV was introduced into the cultures of uninfected H9 cells in a cell population which could not expand and support HIV replication. We have previously found that mitomycin C (MMC)-treated HIV-infected H9 cells can 0 no toxin 0 dO-3 Figure 4 . tained in 12.0 nM as compared to 6.0-nM CD4-PE. The onset of HIV replication was clearly delayed in the cultures treated with 6.0 nM and 12.0-nM CD4-PE, with RT activity only one tenth that ofthe control cultures on day 7. However, by day 10 of culture, only 3 d after removal of CD4-PE, RT activity in supernatants ofthe CD4-PE-treated cell populations was equal to that of the control cells. CD4-PE does not inhibit transmission ofHIVfrom infected to uninfected PBLs. Thus, CD4-PE appears to inhibit HIV replication in PBLs, but only transiently. Such a transient inhibition could, however, considerably delay HIV expansion in cell populations susceptible to infection. To assess this possibility, the efficacy of CD4-PE was assessed in another in vitro system. The system chosen for this evaluation was one that should closely approximate the conditions under which a CD4-toxin must work in order to be effective in vivo in the HIV-infected patient. PBLs from an HIV-infected individual were placed in culture with Con A for 4 d. CD8+ cells were then eliminated from these activated PBLs. A similarly prepared CD8+ cell-depleted, Con A-activated PBL population from an uninfected individual was added to these cells and CD4-PE was introduced into these cultured cells. This system, therefore, allowed us to assess the ability of CD4-PE to block transmission of HIV from the rare virus-infected circulating lymphocyte of the individual to other potentially susceptible lymphocytes. Although HIV transmission in this culture system was fully inhibited by an anti-CD4 MAb, neither an inhibition nor a delay in HIV replication was achieved using CD4-PE (Fig. 8) .
Discussion
These studies demonstrate that CD4-PE conjugates inhibit the replication of gpl 60-transfected CHO cells and block replication in virus-infected H9 cells at nanomolar concentrations. However, this inhibition of virus replication does not appear to be complete since virus replication occurs following removal of the toxin conjugates from these cultures. Moreover, CD4-PE conjugates delay but do not inhibit HIV replication in human PBLs.
The CD4-PE conjugates used in these studies appear to be as potent in their ability to inhibit HIV (15) . In the present studies, the ID50 of the CD4-PE constructs for gpl60-transfected CHO cells was 0.0012 nM and complete inhibition of cell replication was observed at a 1.2-nM concentration of CD4-PE. Maximal inhibition of HIV replication in H9 cells was seen using these conjugates at a 6-nM concentration.
In these studies, we explored the use of CD4-PE conjugates in in vitro systems which should be indicative of the value of such conjugates in a therapeutic setting. In studies of monoclonal antibodies coupled to toxins, it has become apparent that delivery of such conjugates to individuals over a prolonged period of time can result in significant toxin-induced nonspecific tissue injury. Moreover, it is also clear that repeated dosing of such conjugates eventually results in the generation of toxin-specific antibody responses that can neutralize the therapeutic efficacy of these molecules (20) . For these reasons it is assumed that toxin conjugates can be used at most intermittently in therapy (20) . We therefore assessed viral replication in vitro before and after removing CD4-PE from cultures of HIV-infected H9 cells. Our observation that viral replication can be demonstrated soon after removal of the CD4-PE-toxin conjugates from these cultured HIV-infected cells is, therefore, troubling.
In further attempts to study the CD4-PE conjugates in physiologically relevant systems, we also assessed the ability of these conjugates to inhibit viral spread from a limited number of HIV-infected PBLs to uninfected PBLs. We were unable to detect CD4-PE inhibition of virus spread from infected to uninfected cells. A number of explanations might be proposed to account for the apparent inefficiency of CD4-PE to inhibit HIV spread and replication under these in vitro conditions. 0 no toxin HIV may spread from cell to cell in lymphocyte populations before envelope glycoprotein is expressed on the surface of these cells in quantities sufficient to make the cells optimal targets for CD4-toxin conjugates. Ifthis, in fact, occurs, the use of the CD4 toxins to inhibit spread of virus in PBLs may be of limited value. CD4 expression is also considerably greater on PBLs than on H9 cells. PBLs may, therefore, be more susceptible to infection by limited numbers of HIV particles than are H9 cells. If this were true, CD4-PE might be less efficient at blocking HIV infection in PBLs than in H9 cells.
The experiments described in these studies do not contradict findings reported by other investigators working with CD4-PE. Chaudhary et al. did not measure HIV replication in CD4-PE-treated cells. They only assessed the proliferative capacity of CV-l cells infected with vaccinia-gp 160 and HIV-infected A3.01 cells after a brief exposure to CD4-PE (13). Till et al. similarly only measured the proliferative activity of CD4-PE-treated HIV-infected H9 cells (14) . Although Berger et al. did demonstrate a CD4-PE-induced inhibition of RT generation by HIV-infected cells in vitro, they studied virus replication only in A3.01 cells (15) . These experiments assessed CD4-PE-mediated inhibition of HIV replication in H9 cells and, more importantly, in human PBLs. Moreover, in the experiments most central to these studies, CD4-PE was assessed for its ability to block transmission of HIV from infected to uninfected PBLs. The kinetics of HIV replication in H9 cells and lectin-activated human PBLs, and the susceptibility of these virus-infected cells to killing by CD4-PE, might be expected to differ substantially from those of HIV-infected A3.01 cells.
While these studies suggest that CD4-PE may not completely eliminate replicating virus from an infected cell population, CD4-toxin conjugates may still prove of value in the therapeutic armamentarium against AIDS. CD4 conjugates prepared with cell toxins more potent than PE may be more efficient at eliminating virus-infected cells than CD4-PE. CD4-toxin conjugates may also prove more toxic in vivo than in vitro. Those issues notwithstanding, the data in the present study clearly demonstrate that CD4-PE does delay the spread of HIV in culture. It is, therefore, possible that such a conjugate may prove a useful adjunct to other modalities of treatment in AIDS.
